Psychometric validation of the Portuguese version of the Neuropathic Pain Symptoms Inventory

Health and Quality of Life Outcomes

Manoel J Teixeira⁴  Didier Bouhassira²  Telma Zakka⁴  Gerson Ballester⁴  Erich T Fonoff⁴  Ricardo Galhardoni⁴  Helena H Kaziyama⁴  Patrick RNAG Stump⁴  Joaci Araujo⁴  Katia de Sá¹  Abrahão F Batista⁵  Lyn T Yeng³  Carine M Nishimura³  Karine ASL Ferreira³  Daniel Ciampi de Andrade³ 

[1] Coordenação de Pós-Graduação, Pesquisa e Extensão, Escola Bahiana de Medicina e Saúde Pública, Brazil;INSERM U-987, CHU Ambroise Paré, APHP, F-92100 Boulogne-Billancourt, France;Instituto do Câncer do Estado de São Paulo Otávio Frias de Oliveira, Brazil;Pain Center, Hospital das Clínicas, Department of Neurology of the University of São Paulo, Brazil;Divisão de Neurologia e Epidemiologia, Universidade Federal da Bahia, Brazil

关键词: questionnaire;    pain assessment;    neuropathic pain;    Portuguese language;    Neuropathic Pain Symptom Inventory;   

Others  :  826215
DOI  :  10.1186/1477-7525-9-107

 received in 2011-07-11, accepted in 2011-11-30,  发布年份 2011

【 摘 要 】

Backgroud

It has been shown that different symptoms or symptom combinations of neuropathic pain (NeP) may correspond to different mechanistic backgrounds and respond differently to treatment. The Neuropathic Pain Symptom Inventory (NPSI) is able to detect distinct clusters of symptoms (i.e. dimensions) with a putative common mechanistic background. The present study described the psychometric validation of the Portuguese version (PV) of the NPSI.

Methods

Patients were seen in two consecutive visits, three to four weeks apart. They were asked to: (i) rate their mean pain intensity in the last 24 hours on an 11-point (0-10) numerical scale; (ii) complete the PV-NPSI; (iii) provide the list of pain medications and doses currently in use. VAS and Global Impression of Change (GIC) were filled out in the second visit.

Results

PV-NPSI underwent test-retest reliability, factor analysis, analysis of sensitivity to changes between both visits. The PV-NPSI was reliable in this setting, with a good intra-class correlation for all items. The factorial analysis showed that the PV-NPSI inventory assessed different components of neuropathic pain. Five different factors were found. The PV-NPSI was adequate to evaluate patients with neuropathic pain and to detect clusters of NeP symptoms.

Conclusions

The psychometric properties of the PV-NPSI rendered it adequate to evaluate patients with both central and peripheral neuropathic pain syndromes and to detect clusters of NeP symptoms.

【 授权许可】

   
2011 de Andrade et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Bennett M: The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001, 92(1-2):147-157.
• [2]Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C: Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008, 136(3):380-387.
• [3]Martinez V, Fletcher D, Martin F, Orlikowski D, Sharshar T, Chauvin M, Bouhassira D, Attal N: Small fibre impairment predicts neuropathic pain in Guillain-Barre syndrome. Pain 2010, 151(1):53-60.
• [4]Jensen MP, Friedman M, Bonzo D, Richards P: The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain 2006, 22(1):97-103.
• [5]Kaki AM, El-Yaski AZ, Youseif E: Identifying neuropathic pain among patients with chronic low-back pain: use of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. Reg Anesth Pain Med 2005, 30(5):422-428.
• [6]Martinez V, Fletcher D, Bouhassira D, Sessler DI, Chauvin M: The evolution of primary hyperalgesia in orthopedic surgery: quantitative sensory testing and clinical evaluation before and after total knee arthroplasty. Anesth Analg 2007, 105(3):815-821.
• [7]Kerba M, Wu JS, Duan Q, Hagen NA, Bennett MI: Neuropathic Pain Features in Patients With Bone Metastases Referred for Palliative Radiotherapy. J Clin Oncol 2010.
• [8]Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepere C, Rougier P, Guirimand F: Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 2009, 144(3):245-252.
• [9]de Andrade DC, Jean S, Clavelou P, Dallel R, Bouhassira D: Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness. BMC Infect Dis 2010, 10:31. BioMed Central Full Text
• [10]Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D: Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 2008, 138(2):343-353.
• [11]Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D: Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology 2002, 58(4):554-563.
• [12]Attal N, Gaude V, Brasseur L, Dupuy M, Guirimand F, Parker F, Bouhassira D: Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology 2000, 54(3):564-574.
• [13]Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D: Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. Eur Neurol 1998, 40(4):191-200.
• [14]Galer BS, Jensen MP: Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997, 48(2):332-338.
• [15]Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, et al.: Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004, 108(3):248-257.
• [16]Crawford B, Bouhassira D, Wong A, Dukes E: Conceptual adequacy of the neuropathic pain symptom inventory in six countries. Health Qual Life Outcomes 2008, 6:62. BioMed Central Full Text
• [17]Gordon RG Jr: Portuguese. Ethnologue: Languages of the World. Volume 1. 15th edition. SIL International; 2005.
• [18]Padua L, Briani C, Jann S, Nobile-Orazio E, Pazzaglia C, Morini A, Mondelli M, Ciaramitaro P, Cavaletti G, Cocito D, et al.: Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. Neurol Sci 2009, 30(2):99-106.
• [19]Villoria J, Rodríguez M, Berro MJ, Stern A, Sánchez-Magro I: Psychometric Validation of the neuropathic pain symptom inventory for its use in Spanish. J Pain Symptom Manage 2011, 42(1):134-46.
• [20]Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J: Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008, 70(18):1630-1635.
• [21]Ewing JA: Detecting alcoholism. The CAGE questionnaire. JAMA 1984, 252(14):1905-1907.
• [22]Simons DG: Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction. J Electromyogr Kinesiol 2004, 14(1):95-107.
• [23]Justins DM: Complex Regional Pain Syndrome. Seattle: IASP Scientific Program Committee (11th World Congress on Pain); 2005.
• [24]Masters Steedman S, Middaugh SJ, Kee WG, Carson DS, Harden RN, Miller MC: Chronic-pain medications: equivalence levels and method of quantifying usage. Clin J Pain 1992, 8(3):204-214.
• [25]Kachigan SK: Multivariate statistical analysis: a conceptual introduction. 2nd edition. New york: Radius Press; 1991.
• [26]Muller R, Buttner P: A critical discussion of intraclass correlation coefficients. Stat Med 1994, 13(23-24):2465-2476.
• [27]Torrance N, Smith BH, Bennett MI, Lee AJ: The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006, 7(4):281-289.
• [28]Potter J, Higginson IJ, Scadding JW, Quigley C: Identifying neuropathic pain in patients with head and neck cancer: use of the Leeds Assessment of Neuropathic Symptoms and Signs Scale. J R Soc Med 2003, 96(8):379-383.
• [29]Perez C, Galvez R, Insausti J, Bennett M, Ruiz M, Rejas J: [Linguistic adaptation and Spanish validation of the LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) scale for the diagnosis of neuropathic pain]. Med Clin (Barc) 2006, 127(13):485-491.
• [30]Yucel A, Senocak M, Kocasoy Orhan E, Cimen A, Ertas M: Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. J Pain 2004, 5(8):427-432.
• [31]Santos JG, Brito JO, Andrade DCd, Kaziyama VM, Ferreira KA, Souza I, Teixeira MJ, Bouhassira D, Baptista AF: Translation to Portuguese and Validation of the Douleur Neuropathique 4 Questionnaire. The Journal of Pain 2010, 11(5):484-490.
• [32]Truini A, Biasiotta A, La Cesa S, Di Stefano G, Galeotti F, Petrucci MT, Inghilleri M, Cartoni C, Pergolini M, Cruccu G: Mechanisms of pain in distal symmetric polyneuropathy: a combined clinical and neurophysiological study. Pain 2010, 150(3):516-521.
• [33]Hatem SM, Attal N, Ducreux D, Gautron M, Parker F, Plaghki L, Bouhassira D: Clinical, functional and structural determinants of central pain in syringomyelia. Brain 2010, 133(11):3409-3422.
• [34]Eisenberg E, Midbari A, Haddad M, Pud D: Predicting the analgesic effect to oxycodone by 'static' and 'dynamic' quantitative sensory testing in healthy subjects. Pain 2010, 151(1):104-109.
• [35]Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS: Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 2002, 96(3):375-383.